English | عربي
  Add to Twitter
New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases    
Phase III FLAURA trial demonstrates 52% risk reduction of CNS disease progression or death in patients treated with Tagrisso (osimertinib) compared to current standard-of-care EGFR-TKIs*